Efficacy and Safety of Ivabradine in an Elderly Patient with Heart Failure with Reduced Ejection Fraction

2021 ◽  
Vol 41 (2) ◽  
pp. 193-196
Author(s):  
Shunsuke Kiuchi ◽  
Shinji Hisatake ◽  
Takayuki Kabuki ◽  
Takashi Oka ◽  
Takahiro Fujii ◽  
...  
Keyword(s):  
Heart Failure ◽  
Elderly Patient ◽  
Ejection Fraction ◽  
Efficacy And Safety ◽  
Reduced Ejection Fraction

scholarly journals Tolerability, Efficacy, and Safety of Bisoprolol vs. Carvedilol in Japanese Patients With Heart Failure and Reduced Ejection Fraction　― The CIBIS-J Trial ―

2019 ◽  
Vol 83 (6) ◽  
pp. 1269-1277
Author(s):  
Hiroyuki Tsutsui ◽  
Shin-ichi Momomura ◽  
Tohru Masuyama ◽  
Yoshihiko Saito ◽  
Issei Komuro ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Japanese Patients ◽  
Efficacy And Safety ◽  
Reduced Ejection Fraction ◽  
Patients With Heart Failure

scholarly journals Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study

2020 ◽  
Vol 72 (6) ◽  
pp. 535-540
Author(s):  
Anil Ranjeetmal Jain ◽  
Rakesh Kumar Aggarwal ◽  
Nanyam Srinivas Rao ◽  
Gauri Billa ◽  
Shankar Kumar
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Ejection Fraction ◽  
Efficacy And Safety ◽  
Reduced Ejection Fraction

scholarly journals Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age

Circulation ◽  
2020 ◽  
Vol 141 (2) ◽  
pp. 100-111 ◽  
Author(s):  
Felipe A. Martinez ◽  
Matteo Serenelli ◽  
Jose C. Nicolau ◽  
Mark C. Petrie ◽  
Chern-En Chiang ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Efficacy And Safety ◽  
Reduced Ejection Fraction

scholarly journals The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review

2022 ◽  
Vol 27 ◽  
pp. 107424842110586
Author(s):  
Rui Zhang ◽  
Xiaotong Sun ◽  
Ya Li ◽  
Wenzheng He ◽  
Hongguang Zhu ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Renin Angiotensin System ◽  
Efficacy And Safety ◽  
Reduced Ejection Fraction ◽  
Neprilysin Inhibitor ◽  
Regulation Of Metabolism ◽  
Angiotensin Receptor Neprilysin Inhibitor ◽  
Peptide System ◽  
Near Future

Heart failure (HF) is one of the leading causes of morbidity and mortality worldwide. Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has been approved for the treatment of HF. At present, there have been few systematic and detailed reviews discussing the efficacy and safety of sacubitril/valsartan in HF. In this review, we first introduced the pharmacological mechanisms of sacubitril/valsartan, including the reduction in the degradation of natriuretic peptides in the natriuretic peptide system and inhibition of the renin-angiotensin system. Then, we summarized the efficacy of sacubitril/valsartan in HF patients with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF) including the reduction in risks of mortality and hospitalization, reversal of cardiac remodeling, regulation of biomarkers of HF, improvement of the quality of life, antiarrhythmia, improving renal dysfunction and regulation of metabolism. Finally, we discussed the safety and tolerability of sacubitril/valsartan in the treatment of HFrEF or HFpEF. Compared with ACEIs/ARBs or placebo, sacubitril/valsartan showed good safety and tolerability, although the risk of hypotension might be high. In conclusion, the overwhelming majority of studies show that sacubitril/valsartan is effective and safe in the treatment of HFrEF patients but that it has little benefit in HFpEF patients. Sacubitril/valsartan will probably be a promising anti-HF drug in the near future.

scholarly journals Efficacy and Safety of Traditional Chinese Medicine Injections for Heart Failure With Reduced Ejection Fraction: A Bayesian Network Meta-Analysis of Randomized Controlled Trials

2021 ◽  
Vol 12 ◽  
Author(s):  
Shanshan Lin ◽  
Qingyang Shi ◽  
Zhao Ge ◽  
Yangxi Liu ◽  
Yawen Cao ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chinese Medicine ◽  
Ejection Fraction ◽  
Bayesian Network ◽  
Meta Analysis ◽  
Left Ventricular ◽  
Controlled Trials ◽  
Efficacy And Safety ◽  
Reduced Ejection Fraction ◽  
Randomized Controlled

Background: Heart failure as an important issue in global public health, has brought a heavy economic burden. Traditional Chinese medicine injections (TCMIs) have significant effects on heart failure with reduced ejection fraction (HFrEF). However, it is difficult for clinicians to identify the differences in clinical efficacy and safety of various TCMIs. The purpose of this study is to compare the efficacy and safety of various TCMIs for treating HFrEF by conducting a Bayesian network meta-analysis (NMA) and to further provide references for clinical decision-making.Methods: The clinical randomized controlled trials of TCMIs for treating HFrEF were searched in seven database from inception to August 3rd, 2021. The Cochrane collaboration’s tool was used to assess the risk of bias. NMA was performed in a Bayesian hierarchical framework. The surface under the cumulative ranking curve (SUCRA), the multi-dimensional efficacy analysis, the comparison-adjusted funnel plot, and the node-splitting analysis were conducted using R software.Results: A total of 107 eligible RCTs involving 9,073 HFrEF patients and 6 TCMIs were included. TCMIs include Huangqi injection (HQ) also called Astragalus injection, Shenfu injection (SF), Shengmai injection (SGM), Shenmai injection (SM), Xinmailong injection (XML), and Yiqifumai lyophilized injection (YQFM). The results of NMA and SUCRA showed that with conventional treatment (CT) as a common control, in terms of clinical efficacy, CT + XML was most effective in New York Heart Association cardiac functional classification efficiency, brain natriuretic peptide, and N-terminal pro-brain natriuretic peptide; the CT + SM was most effective in 6-min walking test, left ventricular end-diastolic diameter, left ventricular end-systolic diameter and cardiac output; the CT + YQFM was most effective in left ventricular ejection fraction; the CT + HQ was most effective in stroke volume; the CT + SF was most effective in Minnesota Living with Heart Failure Questionnaire. In terms of safety, there was no significant difference between CT + TCMIs and CT.Conclusion: This Bayesian network meta-analysis results show that the combination of qualified TCMIs and CT is more effective for HFrEF patients than CT alone, and CT + XML and CT + SM may be one of the potential optimal treatments. Also, the safety of these TCMIs needs to be further observed. However, due to some limitations, the conclusions need to be verified by more large-sample, double-blind, multi-center RCTs.

Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction

2021 ◽  
Author(s):  
Jawad H. Butt ◽  
Kieran F. Docherty ◽  
Mark C. Petrie ◽  
Morten Schou ◽  
Mikhail N. Kosiborod ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Efficacy And Safety ◽  
Men And Women ◽  
Reduced Ejection Fraction
Sign in / Sign up

Export Citation Format

Share Document